OYAGEN is a biotech company focused on developing treatments for HIV (human immunodeficiency virus). It is engaged in discovering, developing, and commercializing pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. The company provides anti-HIV drugs aimed at solving the problems of viral resistance. Additionally, OYAGEN offers method development and testing as a fee-for-service to academic and educational institutions.